Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...
The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
To that end, HHS has granted Moderna $590 million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the Massachusetts-based pharmaceutical firm about 72 ...
In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback